Metastatic Differentiated Thyroid Cancer: When is Systemic Therapy ...

Department of Endocrine Neoplasia and Hormonal Disorders

N E W S L E T T E R Volume 5, Issue 2, 2012

ENDOPERSPECTIVES?

Metastatic Differentiated Thyroid Cancer: When is Systemic Therapy Beyond RAI Warranted?

Maria E. Cabanillas, MD Assistant Professor Department of Endocrine Neoplasia and Hormonal Disorders

Introduction Patients with widely meta-

static differentiated thyroid cancer (DTC; includes papillary, follicular, and Hurthle cell carcinoma) can pose a challenge to physicians, especially those who see few cases of this relatively rare presentation. While the 10 year median survival after the discovery of metastatic disease is 42%, the prognosis can be vastly different among patients and depends on the age of patient, histology, location and size of the distant disease, as well as whether the disease takes up and responds to radioactive iodine (RAI)1. For example, younger patients ( ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download